Longitudinal proteomic profiling reveals increased early inflammation and sustained apoptosis proteins in severe COVID-19

[1]  Roland Eils,et al.  COVID-19 severity correlates with airway epithelium–immune cell interactions identified by single-cell analysis , 2020, Nature Biotechnology.

[2]  Madeleine K. D. Scott,et al.  Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans , 2020, Science.

[3]  Lijuan Xiong,et al.  Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients , 2020, EBioMedicine.

[4]  P. Hjelmstrom,et al.  Enhanced plasma levels of LIGHT in patients with acute atherothrombotic stroke , 2008, Acta neurologica Scandinavica.

[5]  Wenling Wang,et al.  The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice , 2020, Nature.

[6]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[7]  M. Netea,et al.  Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure , 2020, Cell Host & Microbe.

[8]  V. Preedy,et al.  Prospective Cohort Study , 2010 .

[9]  Lin Cheng,et al.  Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19 , 2020, Nature Medicine.

[10]  P. Marik,et al.  A Descriptive Study , 2015 .

[11]  Toshikazu Nakamura,et al.  Hepatocyte growth factor: A regulator of inflammation and autoimmunity. , 2015, Autoimmunity reviews.

[12]  S. Blomqvist,et al.  Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[13]  G. Gao,et al.  Single-Cell Sequencing of Peripheral Mononuclear Cells Reveals Distinct Immune Response Landscapes of COVID-19 and Influenza Patients , 2020, Immunity.

[14]  M. Iadarola,et al.  Antibody profiling by Luciferase Immunoprecipitation Systems (LIPS). , 2009, Journal of visualized experiments : JoVE.

[15]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[16]  J. Mason,et al.  A dynamic COVID-19 immune signature includes associations with poor prognosis , 2020, Nature Medicine.

[17]  Daniel S. Chertow,et al.  Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019 , 2020, The Journal of infectious diseases.

[18]  J. Mikes,et al.  Systems-Level Immunomonitoring from Acute to Recovery Phase of Severe COVID-19 , 2020, Cell Reports Medicine.

[19]  P. Peterson,et al.  LIPS method for the detection of SARS‐CoV‐2 antibodies to spike and nucleocapsid proteins , 2020, European journal of immunology.

[20]  Bruce Guthrie,et al.  Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study , 2020, The Lancet Global Health.

[21]  C. Cunningham-Rundles,et al.  A serological assay to detect SARS-CoV-2 seroconversion in humans , 2020, Nature Medicine.

[22]  G. Gao,et al.  Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19 , 2020, Journal of Allergy and Clinical Immunology.

[23]  Lei Liu,et al.  Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 , 2020, medRxiv.

[24]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[25]  W. Wang,et al.  Viral and host factors related to the clinical outcome of COVID-19 , 2020, Nature.

[26]  Shangen Zheng,et al.  Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2 , 2020, Journal of Clinical Microbiology.

[27]  Zhenyu Li,et al.  The role of interleukin‐6 in monitoring severe case of coronavirus disease 2019 , 2020, EMBO molecular medicine.

[28]  W. Carson.  Understanding COVID-19 , 2023, Use of Patented Traditional Chinese Medicine against COVID-19.

[29]  P. Lim,et al.  Antibody Response of Patients with Severe Acute Respiratory Syndrome (SARS) Targets the Viral Nucleocapsid , 2004, The Journal of infectious diseases.

[30]  H. Wang,et al.  Serum Protein Profiling Reveals a Landscape of Inflammation and Immune Signaling in Early-stage COVID-19 Infection , 2020, Molecular & Cellular Proteomics.

[31]  Fang Lin,et al.  Clinical and pathological investigation of severe COVID-19 patients. , 2020, JCI insight.

[32]  Eric Song,et al.  Longitudinal analyses reveal immunological misfiring in severe COVID-19 , 2020, Nature.

[33]  Dennis Andersson,et al.  A retrospective cohort study , 2018 .

[34]  Linqi Zhang,et al.  Human neutralizing antibodies elicited by SARS-CoV-2 infection , 2020, Nature.

[35]  C. Hunter,et al.  Cytokine Storms: Understanding COVID-19 , 2020, Immunity.

[36]  R. Davey,et al.  Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019 , 2020, The Journal of Infectious Diseases.

[37]  D. Brodie,et al.  Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study , 2020, The Lancet.

[38]  Fang Lin,et al.  Clinical and pathological investigation of patients with severe COVID-19 , 2020, JCI Insight.

[39]  B. Fevang,et al.  Increased expression of LIGHT/TNFSF14 and its receptors in experimental and clinical heart failure ☆ , 2008, European journal of heart failure.